Jul 25, 2019
TARIS Announces Presentation of Clinical Data for TAR-302 for Overactive Bladder
May 15, 2019
URO-1, Inc. Announces US Patent Issuance for Repris(TM) Bladder Injection System
May 01, 2019
TARIS Bio Initiates New Clinical Study of TAR-302 in Overactive Bladder
Apr 25, 2019
AUA Announces Update to its Overactive Bladder Clinical Practice Guideline
Feb 19, 2019
Bioness StimRouter® Neuromodulation System Receives European CE Mark Approval for the Treatment of Overactive Bladder (OAB)
Jan 03, 2019
TARIS Appoints Tony Kingsley as President and Chief Executive Officer
Apr 24, 2018
Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Jan 17, 2018
Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA
Nov 16, 2017
Nearly 3,000 Women Across America Reveal Surprising Lengths and Locations They've Had to Go to Answer Nature's Urgent Call
Nov 15, 2017
Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension
Nov 14, 2017
Overactive Bladder Causes Significant Burden, Regardless of Age Amongst Adults
Nov 09, 2017
Valencia Technologies to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum
Sep 28, 2017
Cogentix Medical Makes $2 Million Investment in Israeli Company Developing Innovative and Novel Device for Delivery of Drugs to the Bladder
Jun 06, 2017
Roivant Sciences Launches Urovant to Develop Innovative Therapies in Urology